Outcome of infection with omicron SARS-CoV-2 variant in
patients with hematological malignancies: An EPICOVIDEHA survey
report

BLENNOW, Ola, Jon SALMANTON-GARCIA, Piotr NOWAK, Federico ITRI, Van Doesum JAAP, Alberto LOPEZ-GARCIA, Francesca FARINA, Ozren JAKSIC, Laszlo Imre PINCZES, Yavuz M BILGIN, Iker FALCES-ROMERO, Moraima JIMENEZ, Irati ORMAZABAL-VELEZ, Barbora WEINBERGEROVÁ, Remy DULERY, Zlate STOJANOSKI, Tobias LAHMER, Noemi FERNANDEZ, Jose-angel HERNANDEZ-RIVAS, Verena PETZER, De Jonge NICK, Andreas GLENTHOJ, De Ramon CRISTINA, Monika M BIERNAT, Nicola FRACCHIOLLA, Avinash AUJAYEB, Van Praet JENS, Martin SCHONLEIN, Gustavo-Adolfo MENDEZ, Chiara CATTANEO, Anna GUIDETTI, Mariarita SCIUME, Emanuele AMMATUNA, Raul CORDOBA, Nicole GARCIA-POUTON, Stefanie GRAEFE, Alba CABIRTA, Dominik WOLF, Anna NORDLANDER, Ramon GARCIA-SANZ, Mario DELIA, Berg Venemyr CAROLINE, Clara BRONES, Di Blasi ROBERTA, De Kort ELIZABETH, Stef MEERS, Sylvain LAMURE, Laura SERRANO, Maria MERELLI, Nicola COPPOLA, Rui BERGANTIM, Caroline BESSON, Milena KOHN, Jessica PETITI, Carolina GARCIA-VIDAL, Michelina DARGENIO, Francois DANION, Marina MACHADO, Rebeca BAILEN-ALMOROX, Martin HOENIGL, Giulia DRAGONETTI, Louis Yi Ann CHAI, Chi Shan KHO, Matteo BONANNI, Raphael LIEVIN, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, vol. 97, No 8, p. "E312"-"E317", 6 pp. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.26626.

Other formats: BibTeX LaTeX RIS

@article{2243401,
   author = {Blennow, Ola and SalmantonandGarcia, Jon and Nowak, Piotr and Itri, Federico and Jaap, Van Doesum and LopezandGarcia, Alberto and Farina, Francesca and Jaksic, Ozren and Pinczes, Laszlo Imre and Bilgin, Yavuz M and FalcesandRomero, Iker and Jimenez, Moraima and OrmazabalandVelez, Irati and Weinbergerová, Barbora and Dulery, Remy and Stojanoski, Zlate and Lahmer, Tobias and Fernandez, Noemi and HernandezandRivas, Joseandangel and Petzer, Verena and Nick, De Jonge and Glenthoj, Andreas and Cristina, De Ramon and Biernat, Monika M and Fracchiolla, Nicola and Aujayeb, Avinash and Jens, Van Praet and Schonlein, Martin and Mendez, GustavoandAdolfo and Cattaneo, Chiara and Guidetti, Anna and Sciume, Mariarita and Ammatuna, Emanuele and Cordoba, Raul and GarciaandPouton, Nicole and Graefe, Stefanie and Cabirta, Alba and Wolf, Dominik and Nordlander, Anna and GarciaandSanz, Ramon and Delia, Mario and Caroline, Berg Venemyr and Brones, Clara and Roberta, Di Blasi and Elizabeth, De Kort and Meers, Stef and Lamure, Sylvain and Serrano, Laura and Merelli, Maria and Coppola, Nicola and Bergantim, Rui and Besson, Caroline and Kohn, Milena and Petiti, Jessica and GarciaandVidal, Carolina and Dargenio, Michelina and Danion, Francois and Machado, Marina and BailenandAlmorox, Rebeca and Hoenigl, Martin and Dragonetti, Giulia and Chai, Louis Yi Ann and Kho, Chi Shan and Bonanni, Matteo and Lievin, Raphael and Marchesi, Francesco and Cornely, Oliver A and Pagano, Livio},
   article_location = {Hoboken},
   article_number = {8},
   doi = {http://dx.doi.org/10.1002/ajh.26626},
   keywords = {omicron SARS-CoV-2 variant; hematological malignancies},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ajh.26626},
   volume = {97},
   year = {2022}
}

TY  - JOUR
ID  - 2243401
AU  - Blennow, Ola - Salmanton-Garcia, Jon - Nowak, Piotr - Itri, Federico - Jaap, Van Doesum - Lopez-Garcia, Alberto - Farina, Francesca - Jaksic, Ozren - Pinczes, Laszlo Imre - Bilgin, Yavuz M - Falces-Romero, Iker - Jimenez, Moraima - Ormazabal-Velez, Irati - Weinbergerová, Barbora - Dulery, Remy - Stojanoski, Zlate - Lahmer, Tobias - Fernandez, Noemi - Hernandez-Rivas, Jose-angel - Petzer, Verena - Nick, De Jonge - Glenthoj, Andreas - Cristina, De Ramon - Biernat, Monika M - Fracchiolla, Nicola - Aujayeb, Avinash - Jens, Van Praet - Schonlein, Martin - Mendez, Gustavo-Adolfo - Cattaneo, Chiara - Guidetti, Anna - Sciume, Mariarita - Ammatuna, Emanuele - Cordoba, Raul - Garcia-Pouton, Nicole - Graefe, Stefanie - Cabirta, Alba - Wolf, Dominik - Nordlander, Anna - Garcia-Sanz, Ramon - Delia, Mario - Caroline, Berg Venemyr - Brones, Clara - Roberta, Di Blasi - Elizabeth, De Kort - Meers, Stef - Lamure, Sylvain - Serrano, Laura - Merelli, Maria - Coppola, Nicola - Bergantim, Rui - Besson, Caroline - Kohn, Milena - Petiti, Jessica - Garcia-Vidal, Carolina - Dargenio, Michelina - Danion, Francois - Machado, Marina - Bailen-Almorox, Rebeca - Hoenigl, Martin - Dragonetti, Giulia - Chai, Louis Yi Ann - Kho, Chi Shan - Bonanni, Matteo - Lievin, Raphael - Marchesi, Francesco - Cornely, Oliver A - Pagano, Livio
PY  - 2022
TI  - Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
JF  - American Journal of Hematology
VL  - 97
IS  - 8
SP  - "E312"-"E317"
EP  - "E312"-"E317"
PB  - John Wiley & Sons
SN  - 03618609
KW  - omicron SARS-CoV-2 variant
KW  - hematological malignancies
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ajh.26626
N2  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.
ER  -

Basic information
Original name	Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Authors	BLENNOW, Ola, Jon SALMANTON-GARCIA (guarantor), Piotr NOWAK, Federico ITRI, Van Doesum JAAP, Alberto LOPEZ-GARCIA, Francesca FARINA, Ozren JAKSIC, Laszlo Imre PINCZES, Yavuz M BILGIN, Iker FALCES-ROMERO, Moraima JIMENEZ, Irati ORMAZABAL-VELEZ, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Remy DULERY, Zlate STOJANOSKI, Tobias LAHMER, Noemi FERNANDEZ, Jose-angel HERNANDEZ-RIVAS, Verena PETZER, De Jonge NICK, Andreas GLENTHOJ, De Ramon CRISTINA, Monika M BIERNAT, Nicola FRACCHIOLLA, Avinash AUJAYEB, Van Praet JENS, Martin SCHONLEIN, Gustavo-Adolfo MENDEZ, Chiara CATTANEO, Anna GUIDETTI, Mariarita SCIUME, Emanuele AMMATUNA, Raul CORDOBA, Nicole GARCIA-POUTON, Stefanie GRAEFE, Alba CABIRTA, Dominik WOLF, Anna NORDLANDER, Ramon GARCIA-SANZ, Mario DELIA, Berg Venemyr CAROLINE, Clara BRONES, Di Blasi ROBERTA, De Kort ELIZABETH, Stef MEERS, Sylvain LAMURE, Laura SERRANO, Maria MERELLI, Nicola COPPOLA, Rui BERGANTIM, Caroline BESSON, Milena KOHN, Jessica PETITI, Carolina GARCIA-VIDAL, Michelina DARGENIO, Francois DANION, Marina MACHADO, Rebeca BAILEN-ALMOROX, Martin HOENIGL, Giulia DRAGONETTI, Louis Yi Ann CHAI, Chi Shan KHO, Matteo BONANNI, Raphael LIEVIN, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO.
Edition	American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30205 Hematology
Country of publisher	United States of America
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 12.800
RIV identification code	RIV/00216224:14110/22:00127656
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1002/ajh.26626
UT WoS	000816988100001
Keywords in English	omicron SARS-CoV-2 variant; hematological malignancies
Tags	14110212, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 4/1/2023 12:34.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.

PrintDisplayed: 21/7/2024 04:06

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: ...

Other applications